These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 18841188)

  • 21. Updating the French method for the causality assessment of adverse drug reactions.
    Arimone Y; Bidault I; Dutertre JP; Gérardin M; Guy C; Haramburu F; Hillaire-Buys D; Meglio C; Penfornis C; Théophile H; Valnet-Rabier MB;
    Therapie; 2013; 68(2):69-76. PubMed ID: 23773347
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of pharmacovigilance system in Ukraine: first results.
    Stefanov O; Sharayeva M; Jajtchenja V
    Pharmacoepidemiol Drug Saf; 2004 Mar; 13(3):197-9. PubMed ID: 15072120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Terappel: description of a computerised database and examples of studies].
    Vial T; Gouraud A; Bernard N
    Therapie; 2014; 69(1):31-8. PubMed ID: 24698186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Centre for Adverse Reactions Monitoring report for the year ending 30 June, 1993.
    Pillans PI; Coulter DM
    N Z Med J; 1994 Nov; 107(990):490-3. PubMed ID: 7970369
    [No Abstract]   [Full Text] [Related]  

  • 25. Privacy issues and the monitoring of sumatriptan in the New Zealand Intensive Medicines Monitoring Programme.
    Coulter DM
    Pharmacoepidemiol Drug Saf; 2001 Dec; 10(7):663-7. PubMed ID: 11980258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pharmacovigilance of medicinal products in Poland--new guidelines].
    Jabłecka A; Korzeniowska K; Balcer-Dymel N
    Przegl Lek; 2012; 69(10):1127-8. PubMed ID: 23421106
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clozapine and myocarditis: a case series from the New Zealand Intensive Medicines Monitoring Programme.
    Hill GR; Harrison-Woolrych M
    N Z Med J; 2008 Oct; 121(1283):68-75. PubMed ID: 18841187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Drug observatories to make practices safer].
    Lanoue MC
    Soins; 2014 Apr; (784):40-2. PubMed ID: 24839684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluating medicines: let's use all the evidence.
    Harrison-Woolrych ML
    Med J Aust; 2007 Jun; 186(12):662. PubMed ID: 17576193
    [No Abstract]   [Full Text] [Related]  

  • 30. Decision support methods for the detection of adverse events in post-marketing data.
    Hauben M; Bate A
    Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Centre for Adverse Reactions Monitoring report for the year ending 30 June, 1994.
    Pillans PI; Coulter DM
    N Z Med J; 1995 Nov; 108(1012):488-91. PubMed ID: 8538979
    [No Abstract]   [Full Text] [Related]  

  • 32. [Update of the French drug reaction assessment method].
    ; Arimone Y; Bidault I; Dutertre JP; Gérardin M; Guy C; Haramburu F; Hillaire-Buys D; Meglio C; Penfornis C; Théophile H; Valnet-Rabier MB
    Therapie; 2011; 66(6):517-25. PubMed ID: 22186077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Users of a regional center of pharmacovigilance].
    Haramburu F; Abraham E; Bégaud B
    Therapie; 1993; 48(5):475-7. PubMed ID: 8146828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacovigilance in China: current situation, successes and challenges.
    Zhang L; Wong LY; He Y; Wong IC
    Drug Saf; 2014 Oct; 37(10):765-70. PubMed ID: 25218237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Veterinary pharmacovigilance. Part 4. Adverse reactions in humans to veterinary medicinal products.
    Woodward KN
    J Vet Pharmacol Ther; 2005 Apr; 28(2):185-201. PubMed ID: 15842307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk management from an Asian/Pacific Rim regulatory perspective.
    McEwen J
    Drug Saf; 2004; 27(8):491-7. PubMed ID: 15154822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Evaluation of declarations of severe adverse effects from the publication of the decree dated 13 March 1995 about the organisation of pharmacovigilance].
    Lelouet H; Morin M; Trenque T; Bidault I; Castot A; Alexandre JM
    Therapie; 1996; 51(5):555-6. PubMed ID: 9138393
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmacovigilance of drug allergy and hypersensitivity using the ENDA-DAHD database and the GALEN platform. The Galenda project.
    Bousquet PJ; Demoly P; Romano A; Aberer W; Bircher A; Blanca M; Brockow K; Pichler W; Torres MJ; Terreehorst I; Arnoux B; Atanaskovic-Markovic M; Barbaud A; Bijl A; Bonadonna P; Burney PG; Caimmi S; Canonica GW; Cernadas J; Dahlen B; Daures JP; Fernandez J; Gomes E; Gueant JL; Kowalski ML; Kvedariene V; Mertes PM; Martins P; Nizankowska-Mogilnicka E; Papadopoulos N; Ponvert C; Pirmohamed M; Ring J; Salapatas M; Sanz ML; Szczeklik A; Van Ganse E; De Weck AL; Zuberbier T; Merk HF; Sachs B; Sidoroff A;
    Allergy; 2009 Feb; 64(2):194-203. PubMed ID: 19178398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is there a need for forensic pharmacovigilance as a specialty?
    Body D; Edwards IR; Hartigan Go K; Healy D; Herxheimer A; Labadie J
    Int J Risk Saf Med; 2011; 23(1):31-42. PubMed ID: 21507784
    [No Abstract]   [Full Text] [Related]  

  • 40. [Reform Act on safety of drug and health products in France: announcement effect, strengthening or upheaval?].
    Maillols-Perroy AC; Tillet Y
    Therapie; 2012; 67(1):1-10. PubMed ID: 22487499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.